OCA
CYTK icon

Octagon Capital Advisors’s Cytokinetics CYTK Stock Holding History

Octagon Capital Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-194,000
Closed -$13.6M – 51
2024
Q1 		$13.6M Buy
194,000
+78,000
+67% +$6.03M 1.63% 20
2023
Q4 		$9.68M Buy
+116,000
New +$4.2M 1.55% 16

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Octagon Capital Advisors's CYTK Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 194,000 shares — an estimated $13.6M sold.

Octagon Capital Advisors first reported a position in CYTK in Q4 2023 and held it in 2 quarters. The position peaked at $13.6M in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 194,000 Cytokinetics shares in Q2 2024, an estimated $13.6M.
  • Octagon Capital Advisors first reported a position in Cytokinetics in Q4 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Cytokinetics position peaked at $13.6M in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.